Results 11 to 20 of about 56,319 (181)

Molecular Understanding of HIV-1 Latency [PDF]

open access: yesAdvances in Virology, 2012
The introduction of highly active antiretroviral therapy (HAART) has been an important breakthrough in the treatment of HIV-1 infection and has also a powerful tool to upset the equilibrium of viral production and HIV-1 pathogenesis.
W. Abbas, G. Herbein
doaj   +4 more sources

HIV-1 Latency in Monocytes/Macrophages [PDF]

open access: yesViruses, 2014
Human immunodeficiency virus type 1 (HIV-1) targets CD4+ T cells and cells of the monocyte/macrophage lineage. HIV pathogenesis is characterized by the depletion of T lymphocytes and by the presence of a population of cells in which latency has been ...
Amit Kumar, Wasim Abbas, Georges Herbein
doaj   +3 more sources

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo. [PDF]

open access: yesPLOS Pathogens, 2015
UNLABELLED: Pharmacologically-induced activation of replication competent proviruses from latency in the presence of antiretroviral treatment (ART) has been proposed as a step towards curing HIV-1 infection.
Brinkmann, C.R.   +18 more
core   +22 more sources

An Integrated Overview of HIV-1 Latency [PDF]

open access: yesCell, 1929
Despite significant advances in our understanding of HIV, a cure has not been realized for the more than 34 million infected with this virus. HIV is incurable because infected individuals harbor cells where the HIV provirus is integrated into the host’s ...
Ruelas, Debbie S., Greene, Warner C.
core   +6 more sources

HibeRNAtion: HIV-1 RNA Metabolism and Viral Latency

open access: yesFrontiers in Cellular and Infection Microbiology, 2022
HIV-1 infection remains non-curative due to the latent reservoir, primarily a small pool of resting memory CD4+ T cells bearing replication-competent provirus.
Raquel Crespo   +4 more
doaj   +4 more sources

A Canadian Survey of Research on HIV-1 Latency-Where Are We Now and Where Are We Heading? [PDF]

open access: yesViruses
Worldwide, almost 40 million people are currently living with HIV-1. The implementation of cART inhibits HIV-1 replication and reduces viremia but fails to eliminate HIV-1 from latently infected cells.
Abdalla AL   +2 more
europepmc   +2 more sources

HIV-1 latency reversal agent boosting is not limited by opioid use. [PDF]

open access: yesJCI Insight
Opioid use may affect the HIV-1 reservoir and its reversal from latency. We studied 47 virally suppressed people with HIV (PWH) and observed that lower concentration of HIV-1 latency reversal agents (LRAs), used with small molecules that did not reverse ...
Lilie T   +11 more
europepmc   +2 more sources

Galectin-1 promotes HIV-1 latency reactivation

open access: yesJournal of Virus Eradication, 2019
J. Rubione   +13 more
doaj   +2 more sources

Transcriptome profiles of latently- and reactivated HIV-1 infected primary CD4+ T cells: A pooled data-analysis

open access: yesFrontiers in Immunology, 2022
The main obstacle to cure HIV-1 is the latent reservoir. Antiretroviral therapy effectively controls viral replication, however, it does not eradicate the latent reservoir. Latent CD4+ T cells are extremely rare in HIV-1 infected patients, making primary
Anne Inderbitzin   +9 more
doaj   +1 more source

FKBP3 Induces Human Immunodeficiency Virus Type 1 Latency by Recruiting Histone Deacetylase 1/2 to the Viral Long Terminal Repeat

open access: yesmBio, 2021
Human immunodeficiency virus type 1 (HIV-1) cannot be completely eliminated because of existence of the latent HIV-1 reservoir. However, the facts of HIV-1 latency, including its establishment and maintenance, are incomplete.
Xinyi Yang   +25 more
doaj   +1 more source

Home - About - Disclaimer - Privacy